GWAS
Our data
EADB-core dataset comprises GWAS data from 17 countries genotyped using ILLUMINA GSA. This represents one of the most homogeneous database in the world for GWAS on Alzheimer’s disease and related disorders.
- 20,301 AD cases and 21,839 controls
- 6,547 MCI cases with at least 2 years of follow-up
- 5,450 patients suffering from vascular/mixed dementia
- 3,170 cases suffering from other related disorders
Map with number of samples per country
DATA BASE
GENOTYPING
COLLABORATION ON GENOTYPING
EADB believes it is essential to encourage collaboration to improve our knowledge of Alzheimer’s disease and related disorders. The EADB and its partners welcome all types of collaborations on genetics and biomarkers.
Please do not hesitate to contact us
SEQUENCING
SEQUENCING
EADB through its ADES component comprises whole exome sequencing data from 5 countries. All sequencing data have been harmonized using a unique QC and calling pipeline (Holstege et al, Nat Genet, 2022).
We have available whole exome sequencing for 7,376 AD cases and 4,318 controls
12,000 whole genome sequencing are in preparation
COLLABORATE ON SEQUENCING
Sequencing data are available for collaboration and after approval by the EADB Steering Committee, at the Genetics Hub. This hub brings the sequencing data together in a secure environment for analysis.
BIOMARKERS
Biomarkers
More than 20,000 plasma samples and 10,000 CSF samples may be available through the EADB in the various participating centres.
In addition, the EADB database is regularly enriched by the quantification of numerous biomarkers, depending on the ancillary projects developed as part of the consortium
COLLABORATE ON BIOMARKERS
As biomarker datasets are highly dynamic and heterogeneous, each request for collaboration is made on a case-by-case basis, depending on the proposed projects and the availability of the requested biomarker quantifications.